News & Events
Crinetics Announces July 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics Pharmaceuticals announces July 2023 inducement grants: the stock options were granted as inducements material to 10 employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4).
READ MORENew Data Demonstrating Stable Biochemical and Symptom Levels with Two-Years of Oral Paltusotine Administration Presented at ENDO 2023
Data from the Crinetics Phase 2 Advance study of oral paltusotine was presented at ENDO 2023, along with proof-of-concept data from programs for primary hyperparathyroidism and thyroid eye disease
READ MORECrinetics Announces June 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics Pharmaceuticals announces June 2023 inducement grants: the stock options were granted as inducements material to 14 employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4).
READ MORECrinetics to Highlight Broad Pipeline at ENDO 2023
Crinetics Pharmaceuticals highlighting broad pipeline at ENDO 2023 with oral and poster presentations on several programs, including candidates for primary hyperparathyroidism and thyroid eye disease
READ MORECrinetics Announces May 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics Pharmaceuticals announces May 2023 inducement grants: the stock options were granted as inducements material to nine employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4).
READ MORECrinetics Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
Crinetics Pharmaceuticals reported financial results and provided an update on first quarter 2023 clinical progress
READ MORECrinetics Announces April 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics Pharmaceuticals announces April 2023 inducement grants: the stock options were granted as inducements material to 15 employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4).
READ MORECrinetics Announces March 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics Pharmaceuticals announces March 2023 inducement grants: the stock options were granted as inducements material to eight employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4).
READ MORETransforming Endocrine Disease Treatment
Be the first to know about the advances we're making in endocrine-rooted care.
Email Signup
Please click CONTINUE below to learn more about a new treatment option. This website contains information about a prescription medicine.
